126 related articles for article (PubMed ID: 22903691)
1. Emerging molecular networks in Burkitt's lymphoma.
Mangani D; Roberti A; Rizzolio F; Giordano A
J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines.
Roberti A; Rizzolio F; Lucchetti C; de Leval L; Giordano A
Cell Cycle; 2011 Jan; 10(1):127-34. PubMed ID: 21200153
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.
Wilda M; Bruch J; Harder L; Rawer D; Reiter A; Borkhardt A; Woessmann W
Leukemia; 2004 Mar; 18(3):584-8. PubMed ID: 14712292
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
6. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.
Scholtysik R; Kreuz M; Klapper W; Burkhardt B; Feller AC; Hummel M; Loeffler M; Rosolowski M; Schwaenen C; Spang R; Stein H; Thorns C; Trümper L; Vater I; Wessendorf S; Zenz T; Siebert R; Küppers R;
Haematologica; 2010 Dec; 95(12):2047-55. PubMed ID: 20823134
[TBL] [Abstract][Full Text] [Related]
7. The regulation of INK4/ARF in cancer and aging.
Kim WY; Sharpless NE
Cell; 2006 Oct; 127(2):265-75. PubMed ID: 17055429
[TBL] [Abstract][Full Text] [Related]
8. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
Gregory MA; Hann SR
Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
12. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
15. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
17. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
18. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
19. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
20. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
